Skip to main content

Table 4 The comparison of average revenue earned per employee across different pharmaceutical companies

From: Open innovation and external sources of innovation. An opportunity to fuel the R&D pipeline and enhance decision making?

Company Type Founded Number of employees Average 10 years (2006–2016) revenue (M$) Revenue per employee ($)
Helsinn NRDO 1976 680 320 470,588
Jazz Pharma NRDO 2003 1040 615 591,346
Tesaro+ NRDO 2010 446 0.45 1010
Puma Biotech++ NRDO 2010 183 0 0
Clovis NRDO 2009 278 0.14 504
Vanda Pharma NRDO 2002 148 38 256,756
Debiopharm NRDO 1979 150 345 2,300,000
Astra Zeneca Large Pharma 1999 59,700 23,000 385,260
Novartis Large Pharma 1996 12,3000 47,000 382,114
Sanofi Large Pharma 2004 110,000 32,500 295,454
Eli Lilly Large Pharma 1876 42,000 21,500 511,905
Bayer Large Pharma 1863 115,000 43,000 373,913
Pfizer Large Pharma 1849 96,500 51,000 528,497
GSK Large Pharma 2000 99,300 26,400 345,619
Amgen Large Biotech 1980 19,200 20,000 1,041,667
  1. NRDO ‘No Research, Development Only’ companies that do not conduct early research and have not chosen to conduct sell and market their own assets; + calculated over 6 years; ++ calculated over 7 years
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us